| Document |
Document Title |
|
WO/2005/102987A1 |
This invention relates to a process for preparing intermediates useful in preparing Valsartan and to a process for preparing the latter, together with synthesis intermediates of formula (IV), (V) and (VI), useful for manufacturing a medi...
|
|
WO/2005/097100A2 |
Use of compounds of formula (I) as antibacterial agents: Formula (I), wherein Z is a carboxyl radical HOC (∼O)-, a carboxyl ester radical, or a carboxyl isostere radical; ring A is an optionally substituted monocyclic aryl, heteroaryl ...
|
|
WO/2005/094805A1 |
A medicine having prostaglandin D2 (PGD2) production inhibitory activity and having as an active ingredient a substance selected from compounds represented by the general formula (I): A-Y-B &lcub wherein A and B each independently repres...
|
|
WO/2005/095334A1 |
The present invention relates to compounds of the Formula (I), wherein R1, R2, R3, m, and n are as defined. Compounds of the Formula (I) have activity inhibiting production of Aβ-peptide. The invention also relates to pharmaceutical com...
|
|
WO/2005/095327A1 |
Novel compounds having kininogenase-inhibitory activity and medicinal uses thereof, specifically, compounds represented by the general formulae (A), (B), (C), (E) and (H) or medicinally acceptable salts thereof: (A) (C) (B) (E) (H) where...
|
|
WO/2005/090297A1 |
The invention relates to sulphonamide derivatives of formula (I), where RC is optionally substituted 4-6-membered heterocyclic ring containing one or more N atoms, or RC is -NR1R2, RA is a group having the formula (A), (B) or (C) RB is h...
|
|
WO/2005/090298A1 |
The invention relates to sulphonamide derivatives of formula (I), where RC is optionally substituted 4-6-membered heterocyclic ring containing one or more N atoms, or RC forms together with the phenyl ring to which it is attached a benzo...
|
|
WO/2005/087751A2 |
The invention relates to novel compounds and also to methods of treating at least one disease, disorder, or condition associated with amyloidosis using such compounds. Amyloidosis refers to a collection of diseases, disorders, and condit...
|
|
WO/2005/087700A2 |
The present invention discloses bisphenyl compounds of the formula (1): wherein R1, R2, R3, R4, R5, R6, X, Y, W are defined herein after. These compounds are useful as pharmaceuticals.
|
|
WO/2005/087215A1 |
The invention relates to acetyl 2-hydroxy-1,3-diaminospirocyclohexanes and derivatives thereof that are useful in treating at least one disease, disorder, and condition associated with amyloidosis. Amyloidosis refers to a collection of d...
|
|
WO/2005/087752A2 |
The invention relates to novel aminoalkanol derivatives and also to methods of treating at least one disease, disorder, or condition associated with amyloidosis using such compounds. Amyloidosis refers to a collection of diseases, disord...
|
|
WO/2005/084658A1 |
Compounds that may have anti-inflammatory activity are of general formula wherein X is O or NR1; Y isOorNR1; R2 is OR1 or C,1-4 alkyl substituted with R3, and R2 is optionally substituted With R4; each R1 is the same or different and is ...
|
|
WO/2005/085215A1 |
A new anticancer agent which is less apt to be discharged from cancer cells and is suitable for use in a local treatment of cancer cells. The anticancer agent contains a catenane compound represented by the chemical formula (I): [Chemica...
|
|
WO/2005/080367A1 |
A compound of Formula (I) or a salt, solvate and chemically protected form thereof, wherein: R5 is an optionally substituted C5-20 aryl or C4-20 alkyl group; A is selected from the group consisting of Formulae (Ai), (Aii), (Aiii) D is se...
|
|
WO/2005/080356A1 |
The present invention relates to new compounds of formula I, wherein P, Q, X1, X2, X3, X4, R1, R2, m and p, are as defined as in formula I, or salts, solvates or solvated salts thereof, processes for their preparation and new intermediat...
|
|
WO/2005/080322A1 |
A novel fluorene characterized by having a fluorene skeleton to which a functional group such as a guanidino group is attached via a carbonyl group, or its salt. This compound has such an advantage as showing a high affinity particularly...
|
|
WO/2005/080340A1 |
Compounds having a formula (1) or a pharmaceutically acceptable salt or prodrug thereof, are provided, and are useful for the treatment of metabolic disorders.
|
|
WO/2005/077895A1 |
The invention provides cytokine production inhibitors useful as preventive or therapeutic agents for diseases accompanied with abnormally enhanced immune function. Cytokine production inhibitors containing as the active ingredient thioam...
|
|
WO/2005/075426A1 |
The present invention relates to novel dipeptidyl peptidase IV (DPP-IV) inhibitors or general formula (1) useful for treating diabetes, non-insulin dependent diabetes mellitus, impaired glucose tolerance, inflammatory bowel disease, ulce...
|
|
WO/2005/075462A1 |
The present invention relates to a process for the manufacture of intermediates that may be used for the manufacture of ARBs (also called angiotension II receptor antagonists or AT1 receptor antagonists) comprising as a common structural...
|
|
WO/2005/075455A2 |
Methods, composition, and intermediates are disclosed that are useful for making 4-Tetrazolyl-4-phenylpiperidine Compounds according to Formula (I), where Ar1 is -C3-C8 cycloalkyl, phenyl, naphthyl, anthryl, phenanthryl or -(5-7-membered...
|
|
WO/2005/075706A1 |
A surface-treating agent improved in heat resistance, adhesion to resins, and wettability by solder. The surface-treating agent for metals is characterized by containing a tetrazole derivative represented by the following general formula...
|
|
WO/2005/068418A1 |
The invention encompasses novel sulfide and disulfide compounds, compositions comprising sulfide and disulfide compounds, and methods useful for treating and preventing cardiovascular diseases, dyslipidemias, dysproteinemias, and glucose...
|
|
WO/2005/068420A1 |
The present invention relates to novel urea and thiourea compounds, compositions comprising urea or thiourea compounds, and methods useful for treating and preventing aging, Alzheimer’s Disease, cancer, cardiovascular disease, diabetic...
|
|
WO/2005/068410A1 |
The present invention relates to novel ether compounds, compositions comprising ether compounds, and methods useful for treating and preventing cardiovascular diseases, dyslipidemias, dysproteinemias, and glucose metabolism disorders com...
|
|
WO/2005/068412A1 |
The present invention relates to novel ketone compounds, compositions comprising ketone compounds, and methods useful for treating and preventing cardiovascular diseases, dyslipidemias, dysproteinemias, and glucose metabolism disorders c...
|
|
WO/2005/062828A2 |
New compounds are provided that may be used to chelute a metal. The compound comprise polyazamacrocyclic compound with at least one phosphonic group substituted on at least one of the aza groups of the polyazamacrocyclic compound. Method...
|
|
WO/2005/063705A1 |
Compounds represented by the general formula (1) or (100) have excellent inhibitory activities against cell adhesion and cell infiltration and are useful as therapeutic or preventive agents for various inflammatory and autoimmune disease...
|
|
WO/2005/063690A1 |
&agr -Hydroxy amide derivatives of the general formula (I) are bradykinin B1 antagonists or inverse agonists useful in the treatment or prevention of symptoms such as pain and inflammation associated with the bradykinin B1 pathway. R2a i...
|
|
WO/2005/058884A2 |
The present invention provides a compound having aggrecanase inhibitory activity and MMP-13 inhibitory activity, and useful as a therapeutic agent for osteoarthritis, rheumatoid arthritis and the like, more specifically, a cyclopropane c...
|
|
WO/2005/058808A1 |
The present invention provides a compound having aggrecanase inhibitory activity and MMP-13 inhibitory activity, and useful as a therapeutic agent for osteoarthritis, rheumatoid arthritis and the like, more specifically, a N-substituted-...
|
|
WO/2005/056508A1 |
The invention relates to a method for the production of tetrahydrogeranylacetone (tetrahydropseudoionone) by means of aldolcondensation of citral with acetone and subsequent hydrogenation. The invention also relates to the utilization of...
|
|
WO/2005/051893A2 |
The present invention relates to novel, non-secosteroidal, hydroxyl substituted, carbon- linked diaryl compounds with vitamin D receptor (VDR) modulating activity that are less hypercalcemic than 1&agr ,25 dihydroxy vitamin D3. These com...
|
|
WO/2005/051929A1 |
The present invention relates to the conversion of aromatic nitriles to tetrazoles, comprising treatment of the cyano compound with trialkyltin chloride and sodium azide optionally in the presence of a phase transfer catalyst. The proces...
|
|
WO/2005/051928A1 |
The present invention relates to processes for the production of tetrazolyl compounds including removing protective groups from an N-protected tetrazolyl compound with organic acids, giving a high yield of the tetrazolyl compound. The co...
|
|
WO/2005/051930A1 |
[PROBLEMS] To provide a modified-protein formation inhibitor that exhibits intense excellent modified-protein formation inhibiting effects without causing any blood pressure drop. [MEANS FOR SOLVING PROBLEMS] There is provided a modified...
|
|
WO/2005/049586A1 |
The patent relates to a new process of synthesis of an antihypertensive agent, N-pentanoyl-N-[[2'-(1H-tetrazole-5-yl)[1,1'-biphenyl]-4-yl]m
ethyl]-L-valine (1), also known under the generic name of valsartan, by selective reaction of N-p...
|
|
WO/2005/048810A2 |
Novel benzamide compounds of Formula (I), Formula (II) and Formula (III, salts, water soluble salts, analogs and radiolabeled counterparts thereof as sigma-2 receptor radiotracers for imaging the proliferative status of solid tumors. A m...
|
|
WO/2005/049587A1 |
The present invention relates to processes for the preparation of pure valsartan. Also provided is a barium salt of valsartan, and a pharmaceutical composition thereof.
|
|
WO/2005/049588A1 |
A process for isolation of valsartan is provided. The process forms solid valsartan having a purity of at least 99 %.
|
|
WO/2005/047236A1 |
The present invention relates to sulfoxide and bis-sulfoxide compounds of formula (I), formula (II), or formula (III), compositions comprising sulfoxide and bis-sulfoxide compounds, and methods useful for treating and preventing cardiova...
|
|
WO/2005/041867A2 |
An improved thrombopoietin mimetic, the choline salt of 2-(3,4-dimethylphenyl)-4-&lcub [2-hydroxy-3'-(1 H-tetrazol-5-yl)biphenyl-3-yl]-hydrazono&rcub -5-methyl-2,4-dihydropyrazol-3-one.
|
|
WO/2005/040121A2 |
The present invention relates to compounds of formula (I), that are novel VR1 antagonists useful in treating pain, inflammatory thermal hyperalgesia, urinary incontinence, or bladder overactivity.
|
|
WO/2005/037257A2 |
The invention relates to medicinally used substances which specifically inhibit peptidases splitting ala-p-nitroanilide. The invention further relates to the use of at least one such substance or at least one pharmaceutical or cosmetic c...
|
|
WO/2005/035484A1 |
A process for the production of N-aryl-2,2,2-trifluoro- acetimidoyl chloride represented by the general formula (2) by reacting a 2,2,2-trifluoro-N-arylacetamide represented by the general formula (1) with both at least one member select...
|
|
WO/2005/033097A1 |
The bioavailability of an anticancer agent is enhanced when the anticancer agent is administered together with a pharmaceutical composition comprising a compound of formula (I) or a pharmaceutically acceptable salt thereof.
|
|
WO/2005/030736A1 |
A description follows of 1,3-diones having general formula (I): together with their use as herbicides for the control of weeds in agricultural crops.
|
|
WO/2005/030704A1 |
The invention relates to the inhibition of histone deacetylase. The invention provides compounds and methods for inhibiting histone deacetylase enzymatic activity. The invention also provides compositions and methods for treating cell pr...
|
|
WO/2005/023260A1 |
A compound of formula (I) wherein the substituents are described in claim 1 for the treatment of psychoses, pain, neurodegenerative disfunction in memory and learning, schizophrenia, dementia and other diseases in which cognitive process...
|
|
WO/2005/023786A1 |
[PROBLEMS] To provide water-soluble tetrazolium compounds which can form formazanes absorbing long-wavelength rays and are excellent in long-term stability in an aqueous solution and which are favorable for the determination of dehydroge...
|
